Estimation of hypolipidemic psillium effect in gastroenterologic patients with lipid metabolism disorders


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim of the research. Studies of hyperlipidemic effect of psyllium in case of its long-term use (from 3 to 6 months) in patients with hyperlipidemia, metabolic syndrome and constipation as a monotherapy and as a part of combined therapy. Material and methods. Multicenter prospective randomized research work was performed. 721 patient from 19 to 91 y.o. with hyperlipidemia and different risk degree of cardiovascular diseases was involved. In dependence of risk degree of lipid metabolism disorders patients got monotherapy with psillium or psillium in combination with statines. Results. Efficacy of monotherapy with psillium as hypolipidemic remedy was fixed in 36,7% of patients with medium risk of cardiovascular diseases development: up to 12th week significant decrease of total cholesterol level to 6,8%, LDL cholesterol - at 10,62%. Up to the end of research work the decrease of that indexes consisted of 8,58 and 12,5%. On the phone of combined therapy (with statines), in spite of higher initial data, the decrease of total cholesterol level was 10,49%, and LDL cholesterol - 13,7%.In the groups of patients with high and very high risk of cardiovascular diseases development the hypolidemic effect of psillium is also proved. On the phone of prolongated treatment by this medicine the bowel evacuation returned to normal in the majority of cases. Conclusion. The possibility and practicability of psillium use in gastroenterologic patients with hyperlipidemia and bowel evacuation disorders as monotherapy and also in combination with statines was proved.

Full Text

Restricted Access

About the authors

Svetlana V. Levchenko

«A.I. Yevdokimov Moscow state university of medicine and dentistry» Federal State Budgetary Educational Institution of Higher Education of the Ministry of Health of Russia

Email: cholerez@mail.ru
PhD, associate professor of the Department of outpatient therapy

Irina A. Komissarenko

«A.I. Yevdokimov Moscow state university of medicine and dentistry» Federal State Budgetary Educational Institution of Higher Education of the Ministry of Health of Russia

Email: komisarenko@mail.ru
MD, professor, professor of the Department of outpatient therapy

References

  1. Гриневич В.Б., Мехтиев С.Н., Ратников В.А., Латышева А.Я., Кравчук Ю.А. Язвенная болезнь и метаболический синдром (механизмы формирования, клинико-инструментальные проявления и подходы к терапии). СПб, 2006. 31 с
  2. Лазебник Л.Б Атеросклероз - болезнь гепатоцита. Экспериментальная и клиническая гастроэнтерология. 2011;11:3-8
  3. Информационный бюллетень № 317, Январь 2015 г. http://www.who.int/mediacentre/factsheets/fs317/ru/
  4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
  5. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996;335:1001-9.
  6. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998;339:1349-57.
  7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
  8. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1 1-58.
  9. Hubacek J.A., Pikhart H., Peasey A., Kubinova R., Bobak M. FTO variant, energy intake, physical activity and basal metabolic rate in Caucasians. The HAPIEE study. Physiol. Res. 2011;60(1):175-83.
  10. Kuulasmaa K., Tunstall-Pedoe H., Dobson A., Fortmann S., Sans S., Tolonen H., Evans A., Ferrario M., Tuomilehto J. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000;355(9205):675-87.
  11. Диагностика и коррекция липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации РКО, V. пересмотр. Москва. Российский кардиологический журнал,:2012;4В1(96):2-32.
  12. Рекомендации по диагностике и лечению дислипидемий 2016. Российский кардиологический журнал. 2017;5:7-77.
  13. Shepherd L., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C., Westendorp R.G.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in Elderly individuals at Risk vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
  14. Amarenco P., Bogousslavsky J., Callahan A. 3rd, Goldstein L.B., Hennerici M., Rudolph A.E., Sillesen H., Simunovic L., Szarek M., Welch K.M., Zivin J.A.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006;355:549-59.
  15. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., Fuller J.H.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685-96.
  16. Сусеков А.В., Зубарева М.Ю., Деев А.Д., Соловьева Е.Ю. Основные результаты Московского исследования по статинам (Moscow Statin Survey, MSS). Сердце. 2006;6:324-8.
  17. Шальнова С.А., Деев Л.Д. Уроки исследования ОСКАР - эпидемиология и особенности терапии пациентов высокого риска в реальной клинической практике 2005-2006 г. Кардиоваскулярная терапия и профилактика. 2007;6(1):47-53.
  18. Лукина Ю.В., Полянская Ю.Н., Толпыгина С.Н., Айду Ф.А., Марцевич С.Ю. и рабочая группа регистра ПРОГНОЗ ИБС: Воронина В.П., Гофман Е.А., Дмитриева Н.А., Деев А.Д., Лерман О.В., Малышева А.М., Медведков Д.И., Неплюхин С.М., Хелия Т.Г. Изучение приверженности лечению статинами у пациентов с хронической ишемической сердца и соответствия гиполипидемической терапии клиническим рекомендациям (по данным регистра ПРОГНОЗ ИБС). Профилактическая медицина. 2014;4:39-43.
  19. Barrett J.A. Faecal incontinence and constipation in the elderly. Falk symposium, № 95, 1996, p. 211 -25.
  20. Diarrhoea and constipation in geriatric practice. Ed. Ratnaike R.N. Cambridge University press, 1999.
  21. Salmoirago-Blotcher E., Crawford S., Jackson E., Ockene J., Ockene I. Constipation and Risk of Cardiovascular Disease among Post-Menopausal Women. Am. J. Med. 2011;124 (8):714-23.
  22. Комиссаренко И.А., Левченко С.В., Сильвестрова С.Ю., Косачева Т.А. Терапия при дивертикулярной болезни и гиперхолестеринемии. Врач. 2012;4:102-7.
  23. Комиссаренко И.А., Левченко С.В., Гудкова Р.Б., Сильвестрова С.Ю. Эффекты длительного применения псиллиума при лечении больных дивертикулярной болезнью толстой кишки. Клинические перспективы гастроэнтерологии, гепатологии. 2014;3:29-36.
  24. Маевская Е.А., Маев И.В., Кучерявый Ю.А., Черемушкин С.В., Андреев Д.Н. Оценка влияния лактулозы или пищевых волокон на динамику показателей липидного профиля у пациентов с функциональным запором и неалкогольным стеато гепатитом. Лечащий врач. 2016;4:117-24.
  25. Свистунов А.А., Осадчук М.А., Буторова Л.И., Токмулина Г.М. Синдром хронического запора в практике терапевта: особенности терапии при сочетанной патологии. Терапевтический архив. 2017;4:69-74.
  26. Lacy B.E., Mearin F., Chang, L., Chey W. D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;150:1393-407.
  27. Ардатская М.Д. Клиническое применение пищевых волокон: [метод. пособие]. М.: 4ТЕ Арт, 2010. 48 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies